Opioids

The researchers examined trends in opioid prescribing in the United States as professional organizations update their pain management guidelines to reduce opioid use.

In a recent study, researchers compared the efficacy of a mindfulness-based treatment vs group psychotherapy for patients with chronic pain and misusing opioids.

Excessive opioid prescribing is associated with higher patient-re

In an effort to improve access to prevention and treatment for opioid dependence, the FDA has prioritized the approval of generic versions of medication-assisted treatment options.

The FDA’s Psychopharmacologic Drugs Advisory Committee recently reviewed and voted on whether to recommend lofexidine, a non-opioid drug, for the management of opioid withdrawal.

The authors of a recent study evaluated the 6-month effectiveness of a new program in treating individuals with substance use disorders. For details about the program, read more.

In a recent study, researchers sough to quantify the effects of opioid prescribing patterns following surgery on the risk of dependence, overdose, or abuse.

Extended-release naltrexone and sublingual buprenorphine-naloxone are pharmacologically distinct interventions to prevent opioid relapse.

After careful consideration, the FDA has requested that a particular opioid analgesic be removed from the market.

The FDA approved Vantrela ER tablets for the management of severe pain requiring daily opioid treatment which alternative treatment options have proven inadequate.